ConnectiCare

Commercial/Healthcare Exchange PA Criteria

Effective: January 1, 2020

Prior Authorization: Northera

Products Affected: Northera **(**droxidopa) oral capsule

Medication Description: Droxidopa is indicated to treat orthostatic hypotension symptoms (ie, dizziness, lightheadedness, and "feeling that you are about to black out") in adults with neurogenic orthostatic hypotension caused by primary autonomic failure (eg, Parkinson disease, multiple system atrophy, or pure autonomic failure), dopamine beta-hydroxylase deficiency, or nondiabetic autonomic neuropathy. Efficacy beyond 2 weeks of treatment has not been established in clinical studies.

Covered Uses: Northera is indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.

Exclusion Criteria: N/A

Required Medical Information:

1. Diagnosis
2. Previous therapy tried/failed

Age Restrictions: N/A

Prescriber Restrictions: Prescribed by, or in consultation with, a cardiologist or a neurologist

Coverage Duration: 1 month

Other Criteria:

1. Patient has a diagnosis of symptomatic NOH due to primary autonomic failure (Parkinsons disease, multiple system atrophy, pure autonomic failure), dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy; AND
2. Patient has a documented intolerance, contraindication, or treatment failure with, an adequate trial of midodrine and fludrocortisone.

References:

Product Information: NORTHERA(R) oral capsules, droxidopa oral capsules. Lundbeck (per FDA), Deerfield, IL, 2017.

ConnectiCare

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	10/15/2019